Last Update

2016-08-10T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Peter Working?

Peter K. Working

Senior Toxicologist and Head of the Experimental Toxicology Group

Genentech , Inc.

HQ Phone: (650) 225-1000

Email: w***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Genentech , Inc.

1 DNA Way

South San Francisco, California 94080

United States

Company Description

Founded more than 30 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening medical conditions. The company, a member of the ... more

Find other employees at this company (17,047)

Background Information

Employment History

Founder and Director of Regulatory Affairs

ZoneOne Pharma

Senior Vice President of Research and Development

Cell Genesys Inc

Director of Pharmacology and Toxicology

SEQUUS Pharmaceuticals , Inc.

Principal

WorkingAdvisors LLC

Vice President, Nonclinical Research and Development

ALZA Corporation

Affiliations

Member, Scientific Advisory Board
Alzeca Biosciences LLC

Fellow
Academy of Toxicological Sciences

Member of the Scientific Program Committee of the Society of Toxicology and the Clinical and Regulatory Affairs Committee
American Society of Gene

Various Advisory Boards
National Institute of Environmental Health Sciences

Board Member
American Board of Toxicology Inc

Founding Member
BioSafe

Education

B.S. degrees

University of California , Davis

MA

Anatomy

University of California , San Francisco

MS

Biochemistry

University of California , Davis

Ph.D.

PhD

Human Anatomy

University of California , Davis

Web References (27 Total References)


Scientific Advisory Board | Alzeca Biosciences, LLC

www.alzeca.com [cached]

Peter Working, PhD

...
He specializes in translational research in the areas of mechanisms of toxicity, nonclinical drug safety and efficacy, pharmacokinetics, and pharmacology for numerous types of products, including cell therapy, gene therapy, small molecules, nanoparticle-encapsulated drugs, and protein therapeutics and monoclonal antibodies.
Dr. Working began his career as a Staff Scientist at the Chemical Industry Institute of Toxicology (CIIT), a non-profit industry-funded research institute in Research Triangle Park, NC. He subsequently became a senior toxicologist and head of the Experimental Toxicology Group in the Department of Safety Evaluation at Genentech, Inc. From there he moved to Sequus Pharmaceuticals (formerly Liposome Technology, Inc.), where he served first as Director of Pharmacology/Toxicology and ultimately as Vice President, R&D, until the company was purchased by ALZA Corporation in 1999. At ALZA, Dr. Working served as VP of Analytical and Nonclinical Sciences until 2001, when he moved to Cell Genesys, Inc., a gene and cell therapy company focused on oncology, as Senior Vice President of Research and Development.
He is certified in General Toxicology by the American Board of Toxicology (ABT) and is a Fellow of the Academy of Toxicological Sciences. Dr. Working holds a Ph.D. in Human Anatomy and an M.S. in Biochemistry from the University of California, Davis, as well as an M.A. in Anatomy from the University of California, San Francisco, and has published over 100 peer-reviewed scientific papers, review articles and book chapters. He has served on various advisory boards, including the Board of Scientific Counselors of the National Institute of Environmental Health Sciences (National Toxicology Program); the Board of Directors of American Board of Toxicology; the Special Emphasis Panel of the NCI RAID and NExT programs; the Scientific Program Committee of the Society of Toxicology; the Clinical and Regulatory Affairs Committee of the American Society of Gene and Cell Therapy and was a founding member of BioSafe, a expert nonclinical safety advisory committee of BIO.


Peter Working - Cell Genesys Executive Committee - Management

www.gvax.com [cached]

Peter K. Working, Ph.D. Senior Vice President, Research and Development

Peter K. Working, Ph.D., joined Cell Genesys in August 2001 and serves as senior vice president, research and development. Prior to joining Cell Genesys, Dr. Working was vice president of analytical and non clinical sciences and principal scientist at ALZA Corporation. Dr. Working has also held various positions with SEQUUS Pharmaceuticals, where he was vice president of research and development, as well as Genentech, Inc. where he served as a senior toxicologist and head of the Experimental Toxicology Group in the Department of Safety Evaluation. Dr. Working holds Ph.D., M.S. and B.S. degrees from the University of California, Davis and the University of California, San Francisco. He brought over 20 years of pharmaceutical research and development experience to Cell Genesys, including 13 years in the biotechnology industry.


Peter Working - Cell Genesys Executive Committee - Management

www.cellgenesys.com [cached]

Peter K. Working, Ph.D.Senior Vice President, Research and Development

Peter K. Working, Ph.D., joined Cell Genesys in August 2001 and serves as senior vice president, research and development.Prior to joining Cell Genesys, Dr. Working was vice president of analytical and non clinical sciences and principal scientist at ALZA Corporation.Dr. Working has also held various positions with SEQUUS Pharmaceuticals, where he was vice president of research and development, as well as Genentech, Inc. where he served as a senior toxicologist and head of the Experimental Toxicology Group in the Department of Safety Evaluation.Dr. Working holds Ph.D., M.S. and B.S. degrees from the University of California, Davis and the University of California, San Francisco.He brought over 20 years of pharmaceutical research and development experience to Cell Genesys, including 13 years in the biotechnology industry.


Cell Genesys Appoints Peter Working Vice President of Research and Development

www.cellgenesys.com [cached]

FOSTER CITY, Calif., August 29, 2001--Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Peter K. Working, Ph.D., has joined the company in the new position of vice president, research and development.Dr. Working, who served most recently as vice president of analytical and non-clinical sciences and principal scientist at ALZA Corporation, brings over 20 years of pharmaceutical research and development experience to Cell Genesys including 13 years in the biotechnology industry.Dr. Working, who will report to Joe Vallner, Ph.D., president and chief operating officer, was, in the past, a key member of Dr. Vallner's team at SEQUUS Pharmaceuticals--a team which successfully developed and launched pharmaceutical products including the cancer product, Doxil®.

...
"We are delighted to have Peter join our executive team and believe that Peter's extensive experience in biopharmaceutical product development will prove to be invaluable as we continue to advance multiple product programs into Phase III clinical trials over the next eighteen months," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys.
...
Dr. Working, 53, previously with ALZA Corporation, has also held various positions with SEQUUS Pharmaceuticals, where he served as vice president of research and development, as well as Genentech, Inc. where he served as a senior toxicologist and head of the Experimental Toxicology Group in the Department of Safety Evaluation.Dr. Working holds Ph.D., M.S. and B.S. degrees from the University of California, Davis and the University of California, San Francisco.
Cell Genesys is focused on the development and commercialization of cancer vaccines and gene therapies to treat major, life-threatening diseases.The company is conducting clinical trials of GVAX® cancer vaccines in prostate cancer, lung cancer, pancreatic cancer and myeloma and expects to initiate new studies in acute leukemia during 2001.Preclinical stage programs include gene therapies for cancer, hemophilia and cardiovascular disorders.Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for central nervous system disorders.Cell Genesys also continues to hold a 10.5 percent equity interest in its former subsidiary, Abgenix, an antibody product company.Additionally, on August 2, 2001, Cell Genesys announced that it entered into a definitive agreement, expected to close in 30 days, for the acquisition of Calydon, Inc., a private biotechnology company focused on developing therapeutic products for cancer.


Cell Genesys Fact Sheet - Strategic Growth

www.imagesrising.com [cached]

Peter K. Working, Ph.D. Senior Vice President, Research and Development

Cell Genesys, Inc. 500 Forbes Boulevard South San Francisco, CA 94080 650.266.3000 Fax: 650.266.3010

Similar Profiles

Other People with this Name

Other people with the name Working

Russell Working
Ragan Communications Inc

Ryan Working
Wright Ford Young & Co

Stephanie Working
Ellis Funeral Home & Cremation Service

Noel Working

Sara Working
OB-GYN Associates

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory